
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. has demonstrated significant year-over-year growth in its surgical and chronic wound care product lines, particularly with surgical soft tissue repair products seeing a remarkable 24% increase, reaching $23.4 million. The company anticipates continued revenue growth driven by its strategic expansion of distribution partnerships and healthcare facility penetration, with projected topline growth of 13-17% expected in 2026. Additionally, the continuation of profitable operations from the third quarter of 2025 further supports a positive financial outlook, bolstered by anticipated benefits from contracts such as the Vizient agreement.
Bears say
Sanara MedTech reported net revenue of $26.3 million, demonstrating a year-over-year growth of 21.5%, yet this figure fell short of projections by $0.4 million. The company faces several risks, including lower-than-anticipated growth in revenue from its products and services, challenges in acquiring new customers, and the potential inability to launch new offerings, all of which could negatively impact future performance. Additionally, the reduced enterprise value to revenue multiple from 4.3x to 3.0x indicates market concerns, particularly following the departure from telehealth services.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares